Let me note a little specification: the man from Sweden who developed PML in July 2008 has never had been treated before Tysabri...marcstck wrote:...all Tysabri patients should have been on some sort of immunosuppressive or immuno modulating therapy before attempting Tysabri.
Unfortunately some of the Tysabri "cheerleaders" continue to write their messages with this level of misinformation.I'm sorry, but much of the information contained in the above statement is misinformed.
Very obvious to most of us but apparently not to some!If you take the time to read the PDF, I think that will become obvious.
Exactly!! I don't see much difference in the results area than what MS patients have experienced with the CRABs albeit the administration of the drug is much easier. The cost? ....well we are all aware of the initial costs and the huge follow up costs involved. Again, the Tysabri "cheerleaders" see this drug as the saviour of MS patients world-wide....but it is anything but that!!Tysabri has indeed proven to be a very effective drug for many patients. That said, it has also failed many patients, and there are patients who claim that it worsened their condition.as with all pharmaceuticals
I can only assume that his neuro chose to use Tysabri out of desperation because the drug has proven to be ineffective for progressive MS or for patients experiencing an actual exacerbation."In the first case, a treatment-naive male was started on natalizumab after being diagnosed with an aggressive clinical course of multiple sclerosis."
The answer to this questions is very simple....making this kind of information readily available is a disaster for any drug company's' sales. In this case Biogen would be aware of the problems but would minimize them. Often a competitor company will be the one who discovers this information and ensure the public is made aware of it.RuSmolikova wrote:Does anybody know why there is a lack of information about another serious side effects (melanoma, severe liver injury…)
The final costs are ALWAYS covered by the patient and his/her insurance company. If you can recall, just before Tysabri was re-approved by the FDA, Biogen/Elan raised its wholesale cost from just over $ 1800 to about $ 2300 per dose. How do you think they planned to cover the extra costs associated with the re-approval process?!!Who pays additional costs connected with TOUCH and TYGRIS programme? Is it Biogene? Or Elan??
guy I can't let you say this. Thanks for your opinion, Superman. But I don´t believe that France would have an exception from the guideline of EMEA - which suggests TYGRIS program for Europe.superman wrote:TOUCH program. This program is non existent outside of he US, another reason for the cases in Euro.
yeb4432 wrote:In patients on Tysabri whom do not develop neutralizing antibodies it is at least2.5x more effective than the ABCR drugs. This has been established though the trials that initially brought Tysabri to market in 2005.
It is nice to see a response from someone like yourself who can see beyond what Biogen keeps on telling the MS patients and docs. Their marketing department is one of the best in the business when it comes to creating "hype" about their products, especially Tysabri. A few years ago my wife's neuro, who was involved in the Tysabri trials, told me that Biogen's information is simply not trusted in the world of MS medicine.I have been studying for a master degree in bioinformatics. We have had a course about statistics. Data can be presented in many ways. Even that "67%" reduction could be plasmatic. I am not saying that Tysabri does nothing at all. I am saying that we can only see the one side of the coin. The company presenting only the one side and using marketing techniques like gifts to doctors is not a company to be trusted, in my humble opinion.
sou
